Citations

Clear

3942 citation(s) found for "To, Van".

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Renfro, Lindsay A. , Loupakis, Fotios , Adams, Richard , Seymour, Michel , Heinemann, Volker , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph , Bokemeyer, Carsten , Goldberg, Richard M. , Saltz, Leonard B. , Gramont, Aimery de , Lenz, Heinz‐Josef , Adams, Richard A, Seymour, Matthew T, Schmoll, Hans‐Joachim , Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, de Gramont, Aimery, Cutsem, Eric Van , Sargent, Daniel J. , Saltz, Leonard , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | October 26, 2015 | Volume: 34 | Issue: 2 | Pages: 144-150

10.1200/jco.2015.61.6441 | PMID 26503203 Get It

Purpose In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Patients and Methods Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). Results BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m 2 , and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m 2 had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. Conclusion Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
Kalman, LV, Agúndez, JAG, Appell, Malin Lindqvist , Black, J.H., Bell, GC, Boukouvala, Sotiria , Bruckner, Carsten, Bruford, Elspeth A. , Caudle, KE, Coulthard, SA, Daly, Ann K. , Tredici, AL Del, Dunnen, Johan T. den , Drozda, Katarzyna, Everts, Robin E. , Flockhart, David A., Freimuth, Robert R. , Hachad, Houda , Hartshorne, Toinette, Ingelman‐Sundberg, Magnus , Klein, Teri E. , Lauschke, Volker M. , Maglott, DR, McLeod, HL, McMillin, GA, Ua, Meyer, Dj, Müller, Nickerson, D. A., Oetting, WS , Pacanowski, MA, Vm, Pratt, Relling, MV, Roberts, Angharad M. , Ws, Rubinstein, Sangkuhl, Katrin , Schwab, Matthias , Scott, Stuart A. , Sim, SC, Thirumaran, RK, Toji, LH, Tyndale, Rachel F. , Schaik, RHN van, Whirl‐Carrillo, Michelle , Yeo, K. L. B., Zanger, UM, Agúndez, José A. G. , Müller, Daniel J. , Agúndez, JAG, Gaedigk, Andrea , Relling, Mary V. , Toji, Lorraine H., Whirl-Carrillo, Michelle , Agúndez, José A G , Hachad, Houda , Müller, Daniel J , Tyndale, Rachel F , Freimuth, Robert R , Klein, Teri E , Scott, Stuart A , Schwab, Matthias

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 20, 2015 | Volume: 99 | Issue: 2 | Pages: 172-185

10.1002/cpt.280 | PMID 26479518 Get It

This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.
The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin
Sylvester, Richard , Joniau, Steven , Oderda, Marco , Serretta, Vincenzo , Larré, S. , Stasi, Savino M. Di , Rhijn, Bas van, Witjes, Alfred, Grotenhuis, Anne J., Colombo, Renzo , Briganti, Alberto , Babjuk, Marek , Soukup, Viktor , Malats, Núria , Baniel, Jack, Cai, Tommaso , Cha, Eugene K., Ardelt, Peter, Vakarakis, John, Bartoletti, Riccardo , Dalbagni, Guido , Xylinas, Évanguelos , Karnes, R. Jeffrey , Palou, Joan, Karnes, Robert J, Gontero, Paolo , Pisano, Francesca , Malmström, Per‐Uno , Irani, Jacques , Mano, Roy , Cha, Eugene K., Shariat, Shahrokh F. , Malats, Nuria , Joniau, Steven , Oderda, Marco

Mayo Clinic

BJU International | October 15, 2015 | Volume: 118 | Issue: 1 | Pages: 44-52

10.1111/bju.13354 | PMID 26469362 Get It

Objectives To determine if a re‐transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1‐high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1‐HG/G3 initially treated with bacille Calmette–Guérin, 935 (38%) had a re‐TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re‐TUR), group 2 (no muscle, re‐TUR), group 3 (muscle, no re‐TUR) and group 4 (muscle, re‐TUR). Clinical outcomes were compared across the four groups. Results Re‐TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re‐TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re‐TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. Conclusions Our retrospective analysis suggests that re‐TUR may not be necessary in patients with T1‐HG/G3, if muscle is present in the specimen of the primary TUR.
Multi‐disciplinary antimicrobial strategies for improving orthopaedic implants to prevent prosthetic joint infections in hip and knee
Getzlaf, Matthew A., Lewallen, Eric A. , Kremers, Hilal Maradit , Jones, Dakota L. , Bonin, Carolina A. , Dudakovic, Amel , Thaler, Roman , Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Kremers, Hilal M, van Wijnen, Andre J, van Wijnen, Andre J , Maradit Kremers, Hilal

Mayo Clinic

Journal of Orthopaedic Research | October 9, 2015 | Volume: 34 | Issue: 2 | Pages: 177-186

10.1002/jor.23068 | PMID 26449208 Get It

ABSTRACTLike any foreign object, orthopaedic implants are susceptible to infection when introduced into the human body. Without additional preventative measures, the absolute number of annual prosthetic joint infections will continue to rise, and may exceed the capacity of health care systems in the near future. Bacteria are difficult to eradicate from synovial joints due to their exceptionally diverse taxonomy, complex mechanistic attachment capabilities, and tendency to evolve antibiotic resistance. When a primary orthopaedic implant fails from prosthetic joint infection, surgeons are generally challenged by limited options for intervention. In this review, we highlight the etiology and taxonomic groupings of bacteria known to cause prosthetic joint infections, and examine their key mechanisms of attachment. We propose that antimicrobial strategies should focus on the most harmful bacteria taxa within the context of occurrence, taxonomic diversity, adhesion mechanisms, and implant design. Patient‐specific identification of organisms that cause prosthetic joint infections will permit assessment of their biological vulnerabilities. The latter can be targeted using a range of antimicrobial techniques that exploit different colonization mechanisms including implant surface attachment, biofilm formation, and/or hematogenous recruitment. We anticipate that customized strategies for each patient, joint, and prosthetic component will be most effective at reducing prosthetic joint infections, including those caused by antibiotic‐resistant and polymicrobial bacteria. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:177–186, 2016.
Recurrent duplications of 17q12 associated with variable phenotypes
Mitchell, Elyse, Douglas, Andrew G. L. , Kjaegaard, Susanne, Callewaert, Bert , Janssens, Sandra , Yuen, Amy Lawson, Skinner, Cindy , Failla, Pinella , Alberti, A , Avola, Emanuela , Fichera, Marco , Kibæk, Maria, Digilio, M. Cristina , Hannibal, Mark , Hollander, Nicolette S. den , Bizzarri, Veronica, Renieri, Alessandra , Mencarelli, Maria Antonietta , Fitzgerald, Tomas , Piazzolla, Serena, Oudenhove, Elke Van , Romano, Corrado , Schwartz, Charles E. , Rajan, Diana, Crolla, John A., Carter, Nigel, Hodge, Jennelle C. , Vanlander, Arnaud Vincent , Eichler, Evan E , Slavotinek, Anne , Escobar, Luis Fernando , Mefford, Heather C. , Callewaert, Bert , Renieri, Alessandra

Mayo Clinic

American Journal of Medical Genetics Part A | September 30, 2015 | Volume: 167 | Issue: 12 | Pages: 3038-3045

10.1002/ajmg.a.37351 | PMID 26420380 Get It

The ability to identify the clinical nature of the recurrent duplication of chromosome 17q12 has been limited by its rarity and the diverse range of phenotypes associated with this genomic change. In order to further define the clinical features of affected patients, detailed clinical information was collected in the largest series to date (30 patients and 2 of their siblings) through a multi‐institutional collaborative effort. The majority of patients presented with developmental delays varying from mild to severe. Though dysmorphic features were commonly reported, patients do not have consistent and recognizable features. Cardiac, ophthalmologic, growth, behavioral, and other abnormalities were each present in a subset of patients. The newly associated features potentially resulting from 17q12 duplication include height and weight above the 95th percentile, cataracts, microphthalmia, coloboma, astigmatism, tracheomalacia, cutaneous mosaicism, pectus excavatum, scoliosis, hypermobility, hypospadias, diverticulum of Kommerell, pyloric stenosis, and pseudohypoparathryoidism. The majority of duplications were inherited with some carrier parents reporting learning disabilities or microcephaly. We identified additional, potentially contributory copy number changes in a subset of patients, including one patient each with 16p11.2 deletion and 15q13.3 deletion. Our data further define and expand the clinical spectrum associated with duplications of 17q12 and provide support for the role of genomic modifiers contributing to phenotypic variability. © 2015 Wiley Periodicals, Inc.
SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival
Jamshidi, Maral, Investigators, kConFab, Fagerholm, Rainer, Khan, Sofia , Aittomäki, Kristiina , Darabi, Hatef, Li, Jingmei , Andrulis, Irene L. , Chang‐Claude, Jenny, Devilee, Peter , Fasching, Peter A. , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin, Guo, Qi , Rhenius, Valerie , Cornelissen, Sten , Knight, Julia A. , Loehberg, Christian R. , Burwinkel, Barbara , Hopper, John L. , Southey, Melissa C. , Bojesen, Stig E. , Flyger, Henrik, Brenner, Hermann , Holleczek, Bernd , Margolin, Sara , Mannermaa, Arto, Kosma, Veli‐Matti, Dyck, Laurien Van , Nevelsteen, Ines, Giles, Graham G. , McLean, Catriona , Haiman, Christopher A., Henderson, Brian E., Winqvist, Robert , Pylkäs, Katri , Tollenaar, Rob A.�E.�M. , García‐Closas, Montserrat , Figueroa, Jonine D. , Hooning, Maartje J. , Cox, Angela , Cross, Simon S. , Simard, Jacques , Dunning, Alison M. , Easton, Douglas F. , Blomqvist, Carl , Schmidt, Marjanka K. , Durocher, Francine , Thorne, Heather , Investigators, kConFab, Czene, Kamila , Dennis, Joe , Wang, Qin, Rudolph, Anja , Marmé, Frederik , Mannermaa, Arto, Couch, Fergus J. , Olson, Janet E. , Hooning, Maartje J. , Martens, John W.M. , Pharoah, Paul D.P. , Hall, Per N , Nevanlinna, Heli , Giles, Graham G , Southey, Melissa C , Dunning, Alison M , Brenner, Hermann , Cox, Angela , Li, Jingmei , García-Closas, Montserrat , Schmidt, Marjanka K , Michailidou, Kyriaki , Simard, Jacques , Figueroa, Jonine D , Pylkäs, Katri , Devilee, Peter , Bojesen, Stig E , Mclean, Catriona

Mayo Clinic

Oncotarget | September 29, 2015 | Volume: 6 | Issue: 35 | Pages: 37979-37994

10.18632/oncotarget.4991 | PMID 26317411 Get It

Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
Eirin, Alfonso , Zhu, Xiang-Yang, Ebrahimi, Behzad , Krier, James D., Riester, Scott M. , Wijnen, André J. van , Lerman, Lilach O. , Lerman, Amir , van Wijnen, Andre J , Eirin, Alfonso

Mayo Clinic

Cell Transplantation | September 29, 2015 | Volume: 24 | Issue: 10 | Pages: 2041-2053

10.3727/096368914x685582 | PMID 25420012 Get It

Renovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the potent anti-inflammatory properties of MSCs may serve to blunt inflammatory mediators in the cardiorenal axis. However, their relative efficacy in attenuating cardiac injury and dysfunction remains unknown. This study tested the hypothesis that the car-dioprotective effect of EPCs and MSCs delivered into the stenotic kidney in experimental RVH are comparable. Pigs ( n = 7 per group) were studied after 10 weeks of RVH or control untreated or treated with a single intrarenal infusion of autologous EPCs or MSCs 4 weeks earlier. Cardiac and renal function (fast CT) and stenotic kidney release of inflammatory mediators (ELISA) were assessed in vivo, and myocardial inflammation, remodeling, and fibrosis ex vivo. After 10 weeks of RVH, blood pressure was not altered in cell-treated groups, yet stenotic kidney glomerular filtration rate (GFR), blunted in RVH, improved in RVH + EPC, and normalized in RVH + MSCs. Stenotic kidney release of monocyte chemoattractant protein (MCP)-1 and its myocardial expression were elevated in RVH + EPC, but normalized only in RVH + MSC pigs. RVH-induced LV hypertrophy was normalized in both EPC- and MSC-treated pigs, while diastolic function (E/A ratio) was restored to normal levels exclusively in RVH + MSCs. RVH-induced myocardial fibrosis and collagen deposition decreased in RVH + EPCs but further decreased in RVH + MSC-treated pigs. Intrarenal delivery of EPCs or MSCs attenuates RVH-induced myocardial injury, yet MSCs restore diastolic function more effectively than EPCs, possibly by greater improvement in renal function or reduction of MCP-1 release from the stenotic kidney. These observations suggest a therapeutic potential for EPCs and MSCs in preserving the myocardium in chronic experimental RVH.
Ligament Tissue Engineering Using a Novel Porous Polycaprolactone Fumarate Scaffold and Adipose Tissue-Derived Mesenchymal Stem Cells Grown in Platelet Lysate
Wagner, Eric R. , Bravo, Dalibel , Dadsetan, Mahrokh, Riester, Scott M. , Chase, Steven C. , Dietz, Allan B. , Wijnen, André J. van , Yaszemski, Michael J. , Chase, Steven, van Wijnen, Andre J, Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Dietz, Allan B , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | September 28, 2015 | Volume: 21 | Issue: 21-22 | Pages: 2703-2713

10.1089/ten.tea.2015.0183 | PMID 26413793 Get It

How epileptogenic are temporal encephaloceles?
Miller, John W. , Van Gompel, Jamie J, Gompel, Jamie J. Van

Mayo Clinic

Neurology | September 26, 2015 | Volume: 85 | Issue: 17 | Pages: 1440-1441

10.1212/wnl.0000000000002073 | PMID 26408494 Get It